Luke Gammon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Luke Gammon has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Adrian Biddle
Blizard Institute, Barts & The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom
1 shared publication Alice Scemama
Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London
1 shared publicationGehad Youssef
Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London
1 shared publicationHannah Cottom
Department of Cellular Pathology, Barts Health NHS Trust
1 shared publicationIan C Mackenzie
Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London
1 shared publicationKim Piper
Department of Cellular Pathology, Barts Health NHS Trust
1 shared publication
Latest Publications
- Open Access
- 17 November 2023
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 12
Disseminating cells in human oral tumours possess an EMT cancer stem cell marker profile that is predictive of metastasis in image-based machine learning
Cancer stem cells (CSCs) undergo epithelial-mesenchymal transition (EMT) to drive metastatic dissemination in experimental cancer models. However, tumour cells undergoing EMT have not been observed disseminating into the tissue surrounding human tumour specimens, leaving the relevance to human cancer uncertain. We have previously identified both EpCAM and CD24 as CSC markers that, alongside the mesenchymal marker Vimentin, identify EMT CSCs in human oral cancer cell lines. This afforded the opportunity to investigate whether the combination of these three markers can identify disseminating EMT CSCs in actual human tumours. Examining disseminating tumour cells in over 12,000 imaging fields from 74 human oral tumours, we see a significant enrichment of EpCAM, CD24 and Vimentin co-stained cells disseminating beyond the tumour body in metastatic specimens. Through training an artificial neural network, these predict metastasis with high accuracy (cross-validated accuracy of 87–89%). In this study, we have observed single disseminating EMT CSCs in human oral cancer specimens, and these are highly predictive of metastatic disease.
- 17 November 2023
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 12
Open AccessDisseminating cells in human oral tumours possess an EMT cancer stem cell marker profile that is predictive of metastasis in image-based machine learning
Cancer stem cells (CSCs) undergo epithelial-mesenchymal transition (EMT) to drive metastatic dissemination in experimental cancer models. However, tumour cells undergoing EMT have not been observed disseminating into the tissue surrounding human tumour specimens, leaving the relevance to human cancer uncertain. We have previously identified both EpCAM and CD24 as CSC markers that, alongside the mesenchymal marker Vimentin, identify EMT CSCs in human oral cancer cell lines. This afforded the opportunity to investigate whether the combination of these three markers can identify disseminating EMT CSCs in actual human tumours. Examining disseminating tumour cells in over 12,000 imaging fields from 74 human oral tumours, we see a significant enrichment of EpCAM, CD24 and Vimentin co-stained cells disseminating beyond the tumour body in metastatic specimens. Through training an artificial neural network, these predict metastasis with high accuracy (cross-validated accuracy of 87–89%). In this study, we have observed single disseminating EMT CSCs in human oral cancer specimens, and these are highly predictive of metastatic disease.